APA (7th ed.) Citation

Kheraldine, H., Gupta, I., Cyprian, F. S., Vranic, S., Al-Farsi, H. F., Merhi, M., . . . Al Moustafa, A. (2024). Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways. Cancer Cell International, 24(1), 1. https://doi.org/10.1186/s12935-023-03195-z

Chicago Style (17th ed.) Citation

Kheraldine, Hadeel, Ishita Gupta, Farhan Sachal Cyprian, Semir Vranic, Halema F. Al-Farsi, Maysaloun Merhi, Said Dermime, and Ala-Eddin Al Moustafa. "Targeting HER2-positive Breast Cancer Cells by a Combination of Dasatinib and BMS-202: Insight into the Molecular Pathways." Cancer Cell International 24, no. 1 (2024): 1. https://doi.org/10.1186/s12935-023-03195-z.

MLA (9th ed.) Citation

Kheraldine, Hadeel, et al. "Targeting HER2-positive Breast Cancer Cells by a Combination of Dasatinib and BMS-202: Insight into the Molecular Pathways." Cancer Cell International, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12935-023-03195-z.